03.01.2022 - DURHAM, N.C., Jan. 03, 2022 (GLOBE NEWSWIRE) - Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that .
Operator
Good morning, ladies and gentlemen, and welcome to Chimerix first-quarter 2021 earnings conference call. I would now like to introduce you to your host for today s call, Michelle LaSpaluto, vice president of strategic planning and investor relations at Chimerix. Please proceed.
Michelle LaSpaluto
Vice President of Strategic Planning and Investor Relations
Thank you. Good morning, everyone, and welcome to the Chimerix first-quarter 2021 financial and operating results conference call. This morning, we issued a press release, which outlines the topics we plan to discuss today. You can access the press release in our investor s section of the website.
With me on today s call are president and chief executive officer, Mike Sherman; chief medical officer, Allen Melemed; chief financial and business officer, Mike Andriole; chief scientific officer, Randall Lanier; and chief technology officer of imipridones, Josh Allen. Before we begin, I would like to remind you that the